Effect of two different doses of solifenacin succinate therapy (5 mg, 10 mg) for the treatment of ureteral stent (Double J) related symptoms in comparison to placebo

Abstract

Background and objectives: Double-J ureteral stent is widely used in the endourologic surgery. However, it might cause some annoying side effects. This study aimed to evaluate the effect of two different doses of solifenacin (5 mg, 10 mg) on double-J stent-related symptoms after uncomplicated ureteroscopic lithotripsy.Methods: This study involved 120 patients. A total of 80 patients undergoing double-J ureteral stent insertion after ureteroscopic lithotripsy were recruited and provided with solifenacin postoperatively (40 patients received 5 mg and another 40 patients received 10 mg). Another 40 age-and sex-matched patients without solifenacin therapy (received placebo) were enrolled as a placebo group. All patients completed the modified-form Ureteral Symptom Score Questionnaire to evaluate the lower urinary tract symptoms, hematuria and stent-related body pain two weeks following the operation. The severity of stent-related symptoms was compared between the three groups.Results: The mean age was 45.4 years in 5 mg solifenacin group, 48.2 years in the 10 mg solifenacin group and 46.8 years in the placebo group. Compared to the placebo group, both solifenacin groups had significantly lower total symptom score, urgency and urge incontinence scores. Solifenacin groups had significantly less urethral, abdominal and flank pain and hematuria scores. There was no statistically significant difference between the two solifenacin groups of 5 mg and 10 mg. The solifenacin groups versus placebo group showed significant benefits in lower urinary tract symptoms, hematuria and stent-related pain in both genders. Ten subjects encountered minor adverse events in solifenacin groups (8 in the 10 mg group and 2 in the 5 mg group) which was mostly dry mouth and constipation. Conclusion:Postoperative solifenacin was effective and well-tolerated in patients undergoing ureteroscopic lithotripsy and double-J stent indwelling irrespective of genders, particularly for the treatment of stent-related body pain, hematuria and the lower urinary tract symptoms.

Efficacy of Pregabalin, Solifenacin, or Combination Therapy for Ureteral Stent Related Symptoms: A Systematic Review and Meta-Analysis

“…On the other hand, 10 mg solifenacin showed a higher number of minor and selflimited side effects such as headache, constipation, and dry mouth. 9 In this review, most of the studies described headache, constipation, and dry mouth as side effects. Moreover, some studies also described urinary retention, drowsiness, dizziness, and body pain.…”

“…The literature described no significant difference in dosage 5 mg and 10 mg for ureteral stent symptoms, thus we included both dosages in meta analysis. 9 Duration of intervention was within two to four weeks.…”